1 December 2021 in Journal of Clinical and Diagnostic Research
Introduction: Numerous bioactive grafts have been studied for periodontal defect regeneration of which, beta-Tricalcium Phospate (beta-TCP) is a very promising bone graft. Hyaluronic Acid (HA), an essential component of periodontal ligament matrix plays a pivotal role in tissue growth, repair and remodeling. Aim: To evaluate the efficacy of 0.8% HA as an adjunct to beta-TCP in the treatment of isolated human intrabony defects. Materials and Methods: This comparative clinical study was conducted at the Department of Periodontics, SRM Dental College, Chennai, Tamil Nadu, India, from January 2017 and December 2017 (followed-up to June 2018). The study included 30 intrabony defects from 16 chronic periodontitis patients, 15 of each were randomly assigned into either test/control groups and were reviewed till six months. After phase I therapy regenerative osseous surgery was performed at all the sites. Control sites received beta-TCP bone graft alone and test group received beta-TCP with 0.8% HA. Postsurgical clinical evaluation of Probing Pocket depth (PPD) and Clinical Attachment level (CAL) was done at three and six months, radiographs were repeated at six months to assess the bone fill. Statistical analysis using Statistical Package for the Social Sciences (SPSS) version 22.0 was done, Mann-Whitney U test and Wicloxon-Signed Rank test were used to compare the intergroup and intragroup values respectively. Results: The mean age of the control and test groups were 45.7 and 48.5 years respectively. The PPD was reduced, CAL and bone fill were increased in both groups from baseline, indicating clinical effectiveness. From baseline to six months, the PPD reduction and gain in CAL in the test and control groups were 3.27 +/- 0.18 mm, 3.20 +/- 0.18 mm and 3.07 +/- 0.03 mm, 3.07 +/- 0.08 mm, respectively, which was statistically significant (p-value 0.05) in both clinical and radiographic parameters. Conclusion: Hyaluronic acid as an adjunct to beta-TCP demonstrated only comparable outcomes despite obtaining substantial bone fill and attachment gain.
28 January 2025 in Clinical Advances in Periodontics
12 October 2018 in Journal of Young Pharmacists
RSRaghuveer Prabhu Santhakumara
Raghuveer Prabhu Santhakumara
Pomalidomide, an analogue of thalidomide, developed as a third generation oral immunomodulatory antineoplastic agent used for the management of multiple myeloma refractory to both lenolidomide and bortezomib. It exerts a potential immunomodulatory effect in myeloma cells and T lymphocytes. We report a case of 67 year old male patient undergoing treatment for multiple myeloma presented with fever and cough. He was receiving pomalidomide 4 mg, once daily (OD). After taking pomalidomide he developed fever, cough, breathing difficulty and desaturation. He was tachycardiac and tachypenic, auscultation of chest revealed scattered crepts bilateral, ABG (arterial- blood gas) showed hypoxia and chest X-ray showed hilar opacities. MDCT (Multidetector computed tomography) pulmonology angiogram showed no pulmonary thromboembolism, consolidation involving both the lungs, bilateral minimal left pleural effusion and multiple collapsed thoracic vertebra with lytic lesions in all visualized bones. Most commonly reported hematological complaint was dose dependent bone marrow suppression presented by neutropenia, anemia and thrombocytopenia and most commonly reported non-hematological complaints were fatigue, weakness, constipation and back pain. The drug has been rarely known to cause pulmonary toxicity. We document a case report of pomalidomide related pulmonary toxicity in a patient with Multiple Myeloma and conclude that pulmonary toxicity is a potential adverse reaction of pomalidomide treatment and motivate physicians to remain aware of its clinical presentation. Key words: Immunomodulatory effect, Multiple myeloma, Pomalidomide, Pulmonary toxicity.
6 November 2024 in Clinical Advances in Periodontics